PROK
ProKidney Corp. Class AstockNASDAQ
prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney's lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.15 | 2026-11-09 | -10.00% | 3.245 |
| 1M | 1.33 | 2026-10-16 | -22.18% | 2.047 |
| 3M | 1.40 | 2026-08-17 | -26.07% | 1.824 |
| 6M | 1.66 | 2026-05-15 | -37.65% | 1.470 |
| 1Y | 2.25 | 2025-11-17 | -54.00% | 1.819 |
| 2Y | 1.70 | 2024-11-15 | -38.94% | — |
| 5Y | 8.75 | 2022-07-13 | -88.17% | 1.763 |
ProKidney Corp. Class A (NASDAQ:PROK) stock price today is $1.04, and today's volume is 1,443,236. PROK is down 0.957% today. The 30 day average volume is 1.33M. PROK market cap is $216.29M with 208.98M shares outstanding.